ADIPOQ and endometrial cancer: The SRR for each 1 μg/ml increase of adiponectin indicated a 3% reduction in endometrial cancer risk (95% CI: 2%–4%), and a 14% reduction for each increase of 5 μg/ml (95% CI: 9%–19%).